Performance of Two Silicone Hydrogel Toric Contact Lenses

NCT ID: NCT00638846

Last Updated: 2015-05-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

276 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-02-29

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of the clinical performance of two toric contact lenses in a 2-week, single masked (subject), daily wear, randomized, bilateral, parallel group study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vision Correction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

senofilcon A toric

senofilcon A, daily wear, toric contact lens worn for two weeks

Group Type EXPERIMENTAL

senofilcon A toric

Intervention Type DEVICE

silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)

balafilcon A toric

balafilcon A, daily wear, toric contact lens worn for two weeks

Group Type ACTIVE_COMPARATOR

balafilcon A toric

Intervention Type DEVICE

silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

senofilcon A toric

silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)

Intervention Type DEVICE

balafilcon A toric

silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ACUVUE OASYS PureVision Toric

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be between 18 and 45 years of age.
* Sign Written Informed Consent (See separate document).
* Be an existing successful daily wear toric soft contact lens.
* Require a visual correction in both eyes (monovision or uniocular fitting is NOT allowed).
* Does not require presbyopic correction (can read J1 @ normal reading distance).
* Have a sphere requirement in the range -1.00 and -5.00D (-5.25D refractive)
* Have refractive astigmatism between 0.75D and 2.50D in both eyes.
* Achieve visual acuity of 20/30 or better in each eye with spherical distance correction.
* Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:

* No amblyopia.
* No evidence of lid abnormality or infection.
* No conjunctival abnormality or infection.
* No clinically significant slit lamp findings (i.e. stromal edema, vascularisation, infiltrates or abnormal opacities).
* No other active ocular disease.

Exclusion Criteria

* Requires concurrent ocular medication.
* Clinically significant (Grade 3 or 4) corneal stromal haze, corneal vascularisation, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear.
* Corneal staining Grade 3 in more than one region.
* Has had refractive surgery. Has had eye injury/surgery within 8 weeks immediately prior to enrolment for this study.
* Abnormal lacrimal secretions.
* Pre-existing ocular irritation that would preclude contact lens fitting.
* Keratoconus or other corneal irregularity.
* Polymethyl methacrylate (PMMA) or Rigid Gas Permeable (RGP) lens wear in the previous 8 weeks
* Extended lens wear in last 3 months.
* Any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear.
* Diabetic.
* Infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV).
* Pregnancy, lactating or planning a pregnancy at the time of enrolment.
* Participation in any concurrent clinical trial or in last 60 days.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johnson & Johnson Vision Care, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Graeme YOung, MPhil PhD

Role: STUDY_DIRECTOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Camp Eye Care Clinic

North Little Rock, Arkansas, United States

Site Status

James R. Dugue, O.D.

Mission Viejo, California, United States

Site Status

Executive Park Eye Care

Colorado Springs, Colorado, United States

Site Status

Dr. Ted Brink and Associates

Jacksonville, Florida, United States

Site Status

Grene Vision Group

Neodesha, Kansas, United States

Site Status

Advanced Eyecare, PC

Raytown, Missouri, United States

Site Status

Dr. James Brobst

Florence, New Jersey, United States

Site Status

Fine Eye Care Associates

Rochester, New York, United States

Site Status

Warren Ophthalmology Associates

Warren, Ohio, United States

Site Status

Selden Eyecare LLC

Kittanning, Pennsylvania, United States

Site Status

Nittany Eye Associates

State College, Pennsylvania, United States

Site Status

Dr. David W. Ferris and Associates

Warwick, Rhode Island, United States

Site Status

Dr. Larry Menning

Chamberlain, South Dakota, United States

Site Status

Wishnow-Sugar Vision Group

Katy, Texas, United States

Site Status

Dr. William Bogus

Salt Lake City, Utah, United States

Site Status

Midlothian Optometric Center

Midlothian, Virginia, United States

Site Status

The Eye Specialists, Ltd.

Virginia Beach, Virginia, United States

Site Status

The Eye & Contact Lens Clinic

Bremerton, Washington, United States

Site Status

Matus Eyecare

Franklin, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CTOR-501

Identifier Type: -

Identifier Source: secondary_id

CR-0801

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.